RHHBY ROCHE HOLDING AG
- 37.770
- -0.510-1.33%
- 37.810
- +0.040+0.11%
ROCHE HOLDING AG News
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Capricor Stock Rallies 20% on DMD Data Presentation Update
WHO Approves First Mpox Diagnostic Test for Emergency Use
Fitch Confirms Roche's Rating on Strong Pharmaceutical Business Profile
Redburn Atlantic Lowers Price Target on Roche Holding Genusschein AG, Maintains Buy Recommendation
Kepler Capital Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
Eli Lilly and Co (LLY.US) explores new uses for "miracle weight-loss drug" Zepbound, aiming to reduce the incidence of diabetes and other high-risk populations.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lonza Announced Acquisition on March 20
Lonza Has Bought Manufacturing Site in California From Roche for $1.2B
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Roche CEO Eyes Combo Therapies for Obesity-linked Conditions
Roche's Pharma Strategy Signals Obesity Push -- Market Talk
Roche's Sharpened R&D Focus, Cost Discipline Should Clear Productivity Concerns -- Market Talk
Organon Reports Positive Phase 3 Results on Roche Perjuta Biosimilar
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Roche (RHHBY.US) promotes research and development reform, plans to launch 20 new drugs.
Roche plans to launch 20 new drugs to address the diseases causing the greatest burden on society in this decade.
Roche's Giredestrant Gains Combination Potential With Regor's CDK Inhibitor Deal -- Market Talk
Swiss Drugmaker Roche Targets 20 New Medicines by 2029
Roche Confirms Narrowed Pharma Focus, Fast Tracks Obesity-Drug Candidate
Roche to Launch Obesity Drug Candidates Beyond 2028
Analysis
Price Target
No Data
No Data
